Suppr超能文献

酒精和大麻使用与精神分裂症及相关精神病障碍患者的死亡率。

Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.

机构信息

Department of Psychiatry, Treatment Research Program, Maryland Psychiatric Research Center, University of Maryland School of Medicine, 55 Wade Ave., Baltimore, MD 21228, USA.

出版信息

J Psychiatr Res. 2012 Aug;46(8):987-93. doi: 10.1016/j.jpsychires.2012.04.019. Epub 2012 May 16.

Abstract

The impact of co-morbid substance use on mortality is not well studied in psychotic disorders. The objective of this study was to examine the impact of substance use on mortality in people with psychotic disorders and alcohol and/or drug use. We examined the rate of substance use and the risk of substance use on mortality risk over a 4-10 year period in 762 people with psychotic disorders. Deceased patients were identified from the Social Security Death Index and the Maryland Division of Vital Records. Substance use was defined as regular and heavy use or abuse or dependence. Seventy seven percent had co-morbid lifetime substance use, with co-morbid cannabis and alcohol use occurring most commonly. Out of 762 subjects, 62 died during follow up. In a Cox model, predicted mortality risk was higher in age group 35-55 compared to <35 years and in males, but reduced in cannabis users. Overall five- (3.1% vs 7.5%) and ten-year mortality risk (5.5% vs. 13.6%) was lower in cannabis users than in non-users with psychotic disorders (p = 0.005) in a survival model. Alcohol use was not predictive of mortality. We observed a lower mortality risk in cannabis-using psychotic disorder patients compared to cannabis non-users despite subjects having similar symptoms and treatments. Future research is warranted to replicate these findings and to shed light on the anti-inflammatory properties of the endocannabinoid system and its role in decreased mortality in people with psychotic disorders.

摘要

合并物质使用对精神障碍患者死亡率的影响尚未得到充分研究。本研究旨在探讨物质使用对有精神障碍和酒精和/或药物使用的人群死亡率的影响。我们在 762 名精神障碍患者中检查了 4-10 年内物质使用的发生率以及物质使用对死亡率风险的影响。通过社会保障死亡指数和马里兰州生命记录部确定死亡患者。物质使用定义为常规和大量使用或滥用或依赖。77%的人有合并终生物质使用,合并大麻和酒精使用最常见。在 762 名受试者中,有 62 人在随访期间死亡。在 Cox 模型中,与 <35 岁相比,35-55 岁年龄组的预测死亡率风险更高,男性的预测死亡率风险也更高,但大麻使用者的预测死亡率风险降低。在生存模型中,与非使用者相比,有精神障碍的大麻使用者的五年(3.1%比 7.5%)和十年(5.5%比 13.6%)死亡率风险较低(p=0.005)。酒精使用与死亡率无相关性。尽管这些患者有相似的症状和治疗方法,但与非大麻使用者相比,使用大麻的精神障碍患者的死亡率风险较低。需要进一步的研究来复制这些发现,并阐明内源性大麻素系统的抗炎特性及其在精神障碍患者死亡率降低中的作用。

相似文献

1
Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.
J Psychiatr Res. 2012 Aug;46(8):987-93. doi: 10.1016/j.jpsychires.2012.04.019. Epub 2012 May 16.
2
5
The impact of alcohol and illicit drugs on people with psychosis: the second Australian National Survey of Psychosis.
Aust N Z J Psychiatry. 2012 Sep;46(9):864-78. doi: 10.1177/0004867412443900. Epub 2012 Apr 3.
7
Cannabis and schizophrenia: results of a follow-up study.
Eur Arch Psychiatry Clin Neurosci. 1999;249(1):45-9. doi: 10.1007/s004060050064.

引用本文的文献

1
Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials.
Clin Drug Investig. 2025 Sep;45(9):627-642. doi: 10.1007/s40261-025-01465-4. Epub 2025 Aug 1.
4
Alcohol drinking in male patients with chronic schizophrenia: prevalence and its relationship to clinical symptoms.
Front Psychiatry. 2023 Jul 13;14:1164968. doi: 10.3389/fpsyt.2023.1164968. eCollection 2023.
5
Effect of substance use on premature mortality among severely hypertensive African Americans.
J Clin Hypertens (Greenwich). 2022 Apr;24(4):475-482. doi: 10.1111/jch.14420. Epub 2022 Mar 7.
6
Morbidity and mortality in schizophrenia with comorbid substance use disorders.
Acta Psychiatr Scand. 2021 Jul;144(1):42-49. doi: 10.1111/acps.13291. Epub 2021 Mar 8.
7
Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model.
PLoS One. 2020 Mar 12;15(3):e0230238. doi: 10.1371/journal.pone.0230238. eCollection 2020.
8
Total and cause-specific standardized mortality ratios in patients with schizophrenia and/or substance use disorder.
PLoS One. 2018 Aug 23;13(8):e0202028. doi: 10.1371/journal.pone.0202028. eCollection 2018.
9
Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis.
Br J Psychiatry. 2017 Dec;211(6):339-349. doi: 10.1192/bjp.bp.117.200907. Epub 2017 Oct 5.
10
Psychoactive Substance Use by Adults With Schizophrenia Before and During Cannabis Withdrawal.
Prim Care Companion CNS Disord. 2016 Sep 1;18(5). doi: 10.4088/PCC.16l01959.

本文引用的文献

2
The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia.
Schizophr Bull. 2012 Jun;38(4):873-80. doi: 10.1093/schbul/sbq153. Epub 2011 Mar 9.
3
The endocannabinoid system as a target for the treatment of neurodegenerative disease.
Br J Pharmacol. 2010 Jun;160(3):480-98. doi: 10.1111/j.1476-5381.2010.00735.x.
4
Medical marijuana and the law.
N Engl J Med. 2010 Apr 22;362(16):1453-7. doi: 10.1056/NEJMp1000695.
5
Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.
J Clin Psychiatry. 2010 Mar;71(3):304-11. doi: 10.4088/JCP.08m04718yel. Epub 2010 Jan 12.
6
Cigarette smoking and mortality risk in people with schizophrenia.
Schizophr Bull. 2011 Jul;37(4):832-8. doi: 10.1093/schbul/sbp152. Epub 2009 Dec 17.
7
Cannabis use and cognition in schizophrenia.
Front Hum Neurosci. 2009 Nov 24;3:53. doi: 10.3389/neuro.09.053.2009. eCollection 2009.
9
Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders.
Psychopathology. 2009;42(6):350-60. doi: 10.1159/000236906. Epub 2009 Sep 15.
10
Substance abuse-related mortality among middle-aged male VA psychiatric patients.
Psychiatr Serv. 2008 Mar;59(3):290-6. doi: 10.1176/ps.2008.59.3.290.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验